AsMedic

Company Overview

Snapshot

Founded in December 2005, AsMedic operates with 1–10 employees. The company has secured $500K in total capital across one funding round from one investor. AsMedic holds a patent and is currently in the Alpha product stage, focusing on developing its POD product.

Business overview

AsMedic develops solutions for personalized asthma treatment, focusing on the dynamic relationship between airway obstruction and optimal drug dosage. The company's platform technology aims to ensure efficient and personalized drug therapy by delivering preplanned dosages into the lungs, allowing patients to control lung deposition and bioavailability. This approach seeks to improve therapy control and reduce the side effects of inhaled steroids. AsMedic operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Medical Devices, targeting patients globally with its non-invasive inhalation and drug-delivery solutions.

Company Intelligence Q&A

What is AsMedic's primary focus?

AsMedic focuses on developing solutions to address the dynamic relationship between airway obstruction levels and the correct drug dosage for asthma treatment, aiming for efficient and personalized drug therapy.

When was AsMedic founded?

AsMedic was founded in December 2005.

What is the current product stage of AsMedic?

AsMedic's product, POD, is currently in the Alpha stage. This product is designed to ensure efficient and personalized drug therapy by delivering optimal preplanned dosages into the lungs.

What is AsMedic's total disclosed funding?

AsMedic has raised a total of $500K in funding. This was secured in a single A Round in November 2014 from a pharmaceutical company.

Does AsMedic hold any patents?

Yes, AsMedic holds a patent related to its technology.